Karyopharm Therapeutics Inc.
IPOBelievers in the Extraordinary | Karyopharm
Public · Newton, United States · Founded 2008 · $102.2M raised
- Headquarters
- Newton, Massachusetts
- Employees
- 201–500
- Founded
- 2008
- Business Model
- B2B
- Website
- karyopharm.com
- Total Funding
- $102.2M
- Last Round
- $19.0M Series BJul 2013
- Rounds
- 5
- Type
- Public
About
Karyopharm Therapeutics is a commercial-stage pharmaceutical company whose core technology centers on inhibition of nuclear export—specifically XPO1—as a mechanism to treat cancer. The company's lead approved medicine, selinexor (XPOVIO), is indicated for relapsed/refractory multiple myeloma and diffuse large B-cell lymphoma, and Karyopharm continues to develop its pipeline across additional blood cancers and solid tumors.
Summary
Karyopharm Therapeutics Inc. is a Biotech company based in Newton, United States, founded in 2008. It has raised $102.2M in total across 5 rounds, most recently a $19.0M Series B round in Jul 2013. Investors include Chione Ltd, SVB Leerink and Foresite Capital.
Tech & App Stack
4 technologies & apps tracked
Create a free account — 25 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 25 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Nov 2013
Sign up to see all 6 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...